Hunan Mabgeek Biotechnology

Hunan Mabgeek Biotechnology is a clinical-stage biopharmaceutical company founded in 2016, specializing in the development of innovative antibody drugs for allergic, autoimmune, and inflammatory diseases. The company utilizes its proprietary TEADA antibody discovery platform to create highly potent and long-acting therapeutic candidates. Its lead asset, MG-K10 (comekibart), is a long-acting anti-IL-4Rα monoclonal antibody that has reached the NDA stage in China for atopic dermatitis and is in Phase III trials for asthma and prurigo nodularis. Mabgeek has established a strategic partnership with China Medical System for the commercialization of MG-K10 in Greater China and Singapore. The company's pipeline also includes candidates targeting TSLP and MASP-2, positioning it as a significant player in the Th2-mediated disease space.